International Clinical Trial: Incorporate GYS-016 into the treatment regimen for Rifampicin resistance /Multidrug resistance tuberculosis: A Prospective, Single-Center, Open-Label, Randomized Controlled Phase IIa Clinical Trial

Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121616) titled 'Incorporate GYS-016 into the treatment regimen for Rifampicin resistance /Multidrug resistance tuberculosis: A Prospective, Single-Center, Open-Label, Randomized Controlled Phase IIa Clinical Trial' on April 1.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Shanghai Pulmonary Hospital

Condition: Pulmonary Tuberculosis

Intervention: Experimental Group:Based on the 6-month short-course standardized regimen for drug-resistant TB recommended in the WHO Guidelines on Tuberculosis Treatment (6BDLLfxC: BDLLfxC if fluoroquinolone resistance is unknown, BDLLfx if susceptible to fluoroquin...